BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 2670726)

  • 1. [Immunohistochemical analysis of ras gene expression in human melanomas and melanocytic nevi].
    Yasuda H
    Hokkaido Igaku Zasshi; 1989 May; 64(3):243-53. PubMed ID: 2670726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of ras oncogene products among the types of human melanomas and melanocytic nevi.
    Yasuda H; Kobayashi H; Ohkawara A; Kuzumaki N
    J Invest Dermatol; 1989 Jul; 93(1):54-9. PubMed ID: 2664010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
    Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
    Gill M; Cohen J; Renwick N; Mones JM; Silvers DN; Celebi JT
    Cancer; 2004 Dec; 101(11):2636-40. PubMed ID: 15503312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of galanin in melanocytic tumors].
    Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
    Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contribution of monoclonal antibody HMB45 in the histopathologic diagnosis of melanoma].
    Pluot M; Joundi A; Grosshans E
    Ann Dermatol Venereol; 1990; 117(10):691-9. PubMed ID: 1705764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinction of conjunctival melanocytic nevi from melanomas by fluorescence in situ hybridization.
    Busam KJ; Fang Y; Jhanwar SC; Pulitzer MP; Marr B; Abramson DH
    J Cutan Pathol; 2010 Feb; 37(2):196-203. PubMed ID: 20100177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J; Cronin F; Duncan LM
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classifying melanocytic tumors based on DNA copy number changes.
    Bastian BC; Olshen AB; LeBoit PE; Pinkel D
    Am J Pathol; 2003 Nov; 163(5):1765-70. PubMed ID: 14578177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi.
    Gerami P; Wass A; Mafee M; Fang Y; Pulitzer MP; Busam KJ
    Am J Surg Pathol; 2009 Dec; 33(12):1783-8. PubMed ID: 19809275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool.
    Bauer J; Bastian BC
    Dermatol Ther; 2006; 19(1):40-9. PubMed ID: 16405569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
    Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
    J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric DNA analysis of primary cutaneous malignant melanoma.
    Ohnishi K; Ishikawa H
    Acta Derm Venereol; 1991; 71(6):525-8. PubMed ID: 1685836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi.
    Gerami P; Beilfuss B; Haghighat Z; Fang Y; Jhanwar S; Busam KJ
    J Cutan Pathol; 2011 Apr; 38(4):329-34. PubMed ID: 21323721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.